(4-Isobutylphenyl)methanamine | 667906-61-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-Isobutylphenyl)methanamine
• 英文别名: [4-(2-methylpropyl)phenyl]methanamine
• CAS: 667906-61-8
• 化学式: C₁₁H₁₇N
• 分子量: 163.26
• InChiKey: KKOAKBQTSJLRFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• HETEROCYCLIC CETP INHIBITORS
  申请人：Salvati E. Mark

  公开号：US20070161685A1

  公开（公告）日：2007-07-12

  Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.

  式Ia和Ib的化合物 其中A、B、C和R1 如本文所述。
• N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES
  申请人：Salvati Mark E.

  公开号：US20100041717A1

  公开（公告）日：2010-02-18

  Compounds of formula (Ia) and (Ib), wherein A, B, C, R 1 and R 14 are described herein.

  式(Ia)和(Ib)的化合物，其中A、B、C、R1和R14如本文所述。
• Methods for treating anthrax and inhibiting lethal factor
  申请人：Hermes Jeffery D.

  公开号：US20100003276A1

  公开（公告）日：2010-01-07

  This invention relates to a method of inhibiting lethal factor (LF) or for treating anthrax and other conditions related to anthrax infection comprising co-administration of an effective amount of an LF inhibitor and a vaccine to a patient in need of such treatment. Such co-administration unexpectedly provides an effective immune response.

  这项发明涉及一种抑制致死因子（LF）或用于治疗炭疽病和与炭疽感染相关的其他疾病的方法，包括向需要此类治疗的患者联合给予有效剂量的LF抑制剂和疫苗。这种联合给药意外地提供了有效的免疫反应。
• TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE
  申请人：Steinmetzer Torsten

  公开号：US20100022781A1

  公开（公告）日：2010-01-28

  The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.

  该发明涉及一般式（I）的胰蛋白酶样丝氨酸蛋白酶抑制剂，除了抑制纤溶酶外，还抑制血浆激肽原，以及它们的制备和用作药物，优选用于治疗失血，特别是在高纤溶状态、器官移植或心脏手术干预，特别是心肺转流手术中，或作为纤维蛋白粘合剂的组分。
• [EN] MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2<br/>[FR] MODULATEURS DE MORT PROGRAMMÉE DE LIGAND 1 ET/OU DE MORT PROGRAMMÉE DE LIGAND 2
  申请人：SOUTHERN RES INST

  公开号：WO2021113528A1

  公开（公告）日：2021-06-10

  The present disclosure is concerned with dipeptide compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及二肽化合物，用于治疗各种癌症，例如肉瘤、癌瘤、血液系统癌症、实体肿瘤、乳腺癌、宫颈癌、胃肠癌、结直肠癌、脑癌、皮肤癌、前列腺癌、卵巢癌、膀胱癌、甲状腺癌、睾丸癌、胰腺癌、子宫内膜癌、黑色素瘤、胶质母细胞瘤、白血病、淋巴瘤、慢性增生性疾病、骨髓增生异常综合征、增生性肿瘤和浆细胞肿瘤（骨髓瘤）。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。